We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sanofi | EU:SAN | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.28 | -0.31% | 91.02 | 90.80 | 91.02 | 91.95 | 90.81 | 91.30 | 605,355 | 02:01:04 |
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
Paris, July 28, 2022. Read the full press release
Q2 2022 sales growth of 8.1% at CER driven by Dupixent®, Rare Disease, Vaccines and CHC
Q2 2022 business EPS(1) up 16.7% at CER driven by higher sales and improving margins
Progress on Corporate Social Responsibility strategy
Key milestone and regulatory achievements on R&D transformation
Full-year 2022 business EPS guidance revised upward
Sanofi Chief Executive Officer, Paul Hudson, commented:
“Our performance in the second quarter was again marked by higher sales across our key growth drivers and outstanding financial results leading us to upgrade our business EPS guidance for the full-year. Notably, we saw significant growth momentum from our Specialty Care business, mainly driven by Dupixent®. While we continue to increase our investment in R&D, we delivered important pipeline milestones such as the approval of Dupixent® in its fourth disease indication, Eosinophilic Esophagitis. Earlier this month, we had the opportunity to showcase at ISTH the transformative potential of efanesoctocog alfa, the first factor replacement therapy for hemophilia A to receive FDA Breakthrough Therapy Designation. We are also making great progress in advancing our fully integrated social impact strategy, notably in Affordable Access with the launch of Impact®, a dedicated brand for non-profit distribution to enable the secure distribution of 30 Sanofi medicines in 40 lower-income countries. As we continue to deliver ahead of schedule on our Play to Win strategy, we are confident in our business outlook for the second half and as a result, we are reiterating our commitment to achieving the BOI margin target of 30% in 2022.”
Q2 2022 | Change | Change at CER | H1 2022 | Change | Change at CER | |
IFRS net sales reported | €10,116m | +15.7% | +8.1% | €19,790m | +14.2% | +8.4% |
IFRS net income reported | €1,175m | -1.9% | _ | €3,184m | +15.2% | — |
IFRS EPS reported | €0.94 | -2.1% | _ | €2.55 | +15.4% | — |
Free cash flow(3) | €1,535m | +7.5% | _ | €3,242m | -3.3% | — |
Business operating income | €2,753m | +21.5% | +13.2% | €5,818m | +18.7% | +12.7% |
Business net income(1) | €2,170m | +25.4% | +16.6% | €4,594m | +22.6% | +16.3% |
Business EPS(1) | €1.73 | +25.4% | +16.7% | €3.68 | +22.7% | +16.3% |
Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 9). (1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (definition in Appendix 9). The consolidated income statement for Q2 2022 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) 2021 business EPS was €6.56; (3) Free cash flow is a non-GAAP financial measure (definition in Appendix 9).
Read the full press release
Attachment
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions